Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Wednesday. The brokerage issued a hold rating on the stock.

Other equities analysts have also recently issued reports about the company. HC Wainwright decreased their price target on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Northland Capmk downgraded shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, Northland Securities reiterated a “market perform” rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $20.00.

Oncternal Therapeutics Stock Performance

Shares of NASDAQ:ONCT opened at $0.75 on Wednesday. The stock has a market capitalization of $2.21 million, a P/E ratio of -0.06 and a beta of 1.33. The stock’s 50-day moving average price is $1.33 and its 200-day moving average price is $4.71. Oncternal Therapeutics has a 12-month low of $0.62 and a 12-month high of $13.14.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics at the end of the most recent quarter. 16.05% of the stock is currently owned by institutional investors.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.